Avanti Polar Lipids, Inc.

Alabaster, AL 35007

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $6.89MM
First Award Date 09/30/97
Most Recent Award Date 05/01/09

Key Personnel

Last Name Name Awards Contact
Matalon Sadis Matalon 1
Maurer Barry J Maurer 1
Shaw Walter A Shaw 4
Macdonald Robert C Macdonald 1
Burgess Stephen Wayne Burgess 1

8 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-08-051
Budget: 05/01/09 - 01/30/11

DESCRIPTION (provided by applicant): We propose to identify an optimal short carbon chain lipid species to be used as a surrogate for membranes in a novel and improved blood coagulation factor assays that will improve rapid diagnosis of coagulation disorders. Blood coagulation protects the integrity of damaged blood vessels and is localized spec...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/08 - 06/30/10

Individuals with cystic fibrosis (CF) and pancreatic insufficiency (PI) are prone to fat malabsorption, putting them at risk for caloric, essential fatty acid, and choline deficiency, which, in turn, may lead to growth failure and a poorer clinical course. Many subjects with CF have essential fatty acid deficiency, characterized by decreased lev...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/07 - 06/30/08

Individuals with cystic fibrosis (CF) and pancreatic insufficiency (PI) are prone to fat malabsorption, putting them at risk for caloric, essential fatty acid, and choline deficiency, which, in turn, may lead to growth failure and a poorer clinical course. Many subjects with CF have essential fatty acid deficiency, characterized by decreased lev...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/06 - 06/30/07

Individuals with cystic fibrosis (CF) and pancreatic insufficiency (PI) are prone to fat malabsorption, putting them at risk for caloric, essential fatty acid, and choline deficiency, which, in turn, may lead to growth failure and a poorer clinical course. Many subjects with CF have essential fatty acid deficiency, characterized by decreased lev...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 07/15/05 - 05/31/07

DESCRIPTION (provided by applicant): Cationic lipid-like compounds are commonly used in vitro and in vivo to deliver DNA to cells for the purposes of expressing exogenous genes. A number of clinical trials have indicated the promise of these agents for gene therapy, however lipid-based delivery remains less effective than the alternative viral v...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-01-91
Budget: 07/11/03 - 06/30/04

DESCRIPTION (provided by applicant): Our goal is to develop 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) as a clinical inhibitor of ceremide catabolism, in order to enhance the anti-cancer activity of the cytotoxic retinoid, fenretinide (4-HPR). We have reported that 4-HPR increased ceramide in numerous pediatric and adult solid c...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/29/01 - 09/30/02

DESCRIPTION (provided by applicant): A new, innovative and patented lipid matrix composed of lysophosphatidylcholine (LPC), monoglycerides (MG) and fatty acids (FA) is readily absorbed, improving the clinical well-being of cystic fibrosis (CF) patients who have compromised fat absorption in spite of supplemental pancre...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 09/29/99

DESCRIPTION: (Adapted from the Applicant's Abstract). The goal of this project is to increase the efficacy of adenoviral gene transfer in the alveolar epithelium by co-administration of novel lipid products. In aim 1, the novel lipid products will be developed. In aim 2, the extent to which the lipids enhanc...